Medirom Healthcare Technologies Stock Number Of Shares Shorted
| MRM Stock | USD 3.02 0.22 6.79% |
Medirom Healthcare Technologies fundamentals help investors to digest information that contributes to Medirom Healthcare's financial success or failures. It also enables traders to predict the movement of Medirom Stock. The fundamental analysis module provides a way to measure Medirom Healthcare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medirom Healthcare stock.
Medirom | Number Of Shares Shorted |
Medirom Healthcare Technologies Company Number Of Shares Shorted Analysis
Medirom Healthcare's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Medirom Healthcare Number Of Shares Shorted | 10.49 K |
Most of Medirom Healthcare's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medirom Healthcare Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Medirom Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Medirom Healthcare is extremely important. It helps to project a fair market value of Medirom Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Medirom Healthcare's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medirom Healthcare's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medirom Healthcare's interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Medirom Healthcare Technologies has 10.49 K of outstending shares currently sold short by investors. This is 99.84% lower than that of the Health Care Providers & Services sector and 99.87% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 99.78% higher than that of the company.
Medirom Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medirom Healthcare's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medirom Healthcare could also be used in its relative valuation, which is a method of valuing Medirom Healthcare by comparing valuation metrics of similar companies.Medirom Healthcare is currently under evaluation in number of shares shorted category among its peers.
Medirom Healthcare Current Valuation Drivers
We derive many important indicators used in calculating different scores of Medirom Healthcare from analyzing Medirom Healthcare's financial statements. These drivers represent accounts that assess Medirom Healthcare's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Medirom Healthcare's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 7.0B | 6.0B | 3.4B | 3.2B | 4.2B | 5.8B | |
| Enterprise Value | 8.2B | 6.4B | 5.1B | 5.1B | 6.9B | 7.6B |
Medirom Healthcare ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Medirom Healthcare's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Medirom Healthcare's managers, analysts, and investors.Environmental | Governance | Social |
Medirom Fundamentals
| Return On Equity | 1.47 | ||||
| Return On Asset | -0.036 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 39.21 M | ||||
| Shares Outstanding | 4.94 M | ||||
| Shares Owned By Insiders | 40.37 % | ||||
| Number Of Shares Shorted | 10.49 K | ||||
| Price To Book | 10.23 X | ||||
| Price To Sales | 0 X | ||||
| Revenue | 6.83 B | ||||
| Gross Profit | 1.42 B | ||||
| EBITDA | (138.98 M) | ||||
| Net Income | 115.4 M | ||||
| Cash And Equivalents | 354.95 M | ||||
| Cash Per Share | 72.70 X | ||||
| Total Debt | 2.89 B | ||||
| Current Ratio | 0.36 X | ||||
| Book Value Per Share | 43.19 X | ||||
| Cash Flow From Operations | (631.74 M) | ||||
| Short Ratio | 0.01 X | ||||
| Earnings Per Share | 0.15 X | ||||
| Number Of Employees | 390 | ||||
| Beta | 0.04 | ||||
| Market Capitalization | 14.91 M | ||||
| Total Asset | 6.85 B | ||||
| Retained Earnings | 80.28 M | ||||
| Working Capital | (1.8 B) | ||||
| Net Asset | 6.85 B |
About Medirom Healthcare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medirom Healthcare Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medirom Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medirom Healthcare Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Medirom Stock
When determining whether Medirom Healthcare is a strong investment it is important to analyze Medirom Healthcare's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Medirom Healthcare's future performance. For an informed investment choice regarding Medirom Stock, refer to the following important reports:Check out Medirom Healthcare Piotroski F Score and Medirom Healthcare Altman Z Score analysis. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Medirom Healthcare. If investors know Medirom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Medirom Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.582 | Earnings Share 0.15 | Revenue Per Share 1.4 K | Quarterly Revenue Growth (0.06) | Return On Assets (0.04) |
The market value of Medirom Healthcare is measured differently than its book value, which is the value of Medirom that is recorded on the company's balance sheet. Investors also form their own opinion of Medirom Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Medirom Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Medirom Healthcare's market value can be influenced by many factors that don't directly affect Medirom Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Medirom Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Medirom Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Medirom Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.